What the team is known for
Handles complex M&A mandates for global companies investing in Asia, particularly in the pharmaceuticals field, and offers a well-established IP practice especially on the patent protection front, as well as regulatory compliance matters throughout its Asia network. Also advises on issues relating to clinical trial agreements, compliance investigations research, licensing, research and collaboration arrangements. Particularly well placed to handle Australian or Chinese mandates – or deals spanning those jurisdictions.
The team is praised for its efficiency, a client commenting: "They deliver what you ask for; they discuss and bring forward ideas and ways to streamline processes in terms of legal obligations."
Another client adds: "Their advice is practical and to the point, they know where our concern points are and they target their advice to where our concerns are, and their advice is also very commercial as well."
"We always rely on the high quality of their performance," explains one source, who also appreciates how the team can "catch the client's needs."
Acted for George Health Enterprises with regard to a capital raising for its research, development and commercialisation activities.
Acted as sponsor's counsel to BOCI Asia in relation to the listing of EuroEyes on the Hong Kong Stock Exchange.
Bernard O'Shea and Justin Davidson are the practice area heads at the firm's Australia and China offices respectively.